Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

16.370
+0.0500.31%
Volume:2.75M
Turnover:44.79M
Market Cap:43.53B
PE:11.05
High:16.420
Open:16.310
Low:16.200
Close:16.320
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:0.67
T/O Rate:0.51%
Dividend:0.45
Dividend Rate:2.75%
EPS(LYR):1.481
ROE:6.95%
ROA:1.45%
PB:0.77
PE(LYR):11.05
PS:0.88

Loading ...

Sinopharm Group Stock Rallies 1.1% in Hong Kong

Dow Jones
·
Yesterday

Fosun Pharma's H1 Report: Innovative Drug Revenue Surges 13.8% as Global Expansion Spans Three Continents

Deep News
·
Yesterday

Fosun Pharma Posts Flat Profit Growth in H1, Revenue Up 4.8%

MT Newswires Live
·
Yesterday

Press Release: Fosun Pharma Announces 2026 Interim Results

Dow Jones
·
Aug 25

Sinopharm Group Stock Falls 1.9% in Hong Kong

Dow Jones
·
Aug 24

Earning Preview: FOSUN PHARMA this quarter’s revenue is expected to increase by 8.56%, and institutional views are broadly bullish

Earnings Agent
·
Aug 18

Fosun Pharma Subsidiary Enters Collaboration Framework and License Agreement

Stock News
·
Aug 17

Shanghai Fosun's Unit in Collaboration with Sandoz AG on 10 Biologic Products

Reuters
·
Aug 17

Shanghai Fosun Pharmaceutical Says to Team up Sandoz on Commercialization, Development, Manufacturing of up to 10 Biologic Products

THOMSON REUTERS
·
Aug 17

Shanghai Fosun Pharmaceutical Says Unit Signs Framework Cooperation Agreement with Sandoz Ag

THOMSON REUTERS
·
Aug 17

FOSUN PHARMA Subsidiary Starts Phase II Trial of Novel DPP-1 Inhibitor FXS7553 for COPD

Bulletin Express
·
Aug 13

Fosun Pharma Schedules 25 August 2026 Board Meeting to Approve 1H26 Results

Bulletin Express
·
Aug 13

Sinopharm Group Stock Slides 1.3% in Hong Kong

Dow Jones
·
Aug 11

Fosun Pharma Secures China Approval for Two Drugs

MT Newswires Live
·
Aug 10

Fosun Pharma Subsidiary Secures NMPA Approval for Dobutamine Hydrochloride Injection

Bulletin Express
·
Aug 07

Fosun Pharma Secures NMPA Green Light for Levosalbutamol Nebuliser Solution

Bulletin Express
·
Aug 07

Fosun Pharma Launches Head-to-Head Phase 3 Clinical Trial for a First-in-Class Drug

Deep News
·
Aug 07

Fosun Pharma's Dobutamine Hydrochloride Injection Receives NMPA Marketing Approval

Stock News
·
Aug 07

Shanghai Fosun Pharma - Drug Registration Application for Dobutamine Hydrochloride Injection Approved by Nmpa

THOMSON REUTERS
·
Aug 07

Sinopharm Group Stock Sheds 0.8% in Hong Kong

Dow Jones
·
Aug 07